The work is supported by a renewed $3.2 million grant from the National Cancer Institute (National Institutes of Health). The project is building a new drug class intended to weaken cancer’s DNA double-strand break repair while enabling standard treatments to work at lower doses. The focus is lung cancer, where improved responses to radiotherapy could translate into better tumor control and reduced dose-related toxicity.

Led by Dr. Navnath Gavande (Wayne State University) and Dr. John Turchi (Indiana University School of Medicine), the team targets the Ku70/80 complex that sits at the start of the non-homologous end joining (NHEJ) pathway. In NHEJ, Ku recognizes DNA ends and recruits DNA-dependent protein kinase (DNA-PK) to initiate repair. By preventing Ku from binding damaged DNA, the researchers aim to shut down DNA-PK activation at its earliest functional step.

Unlike therapies that inhibit DNA-PK enzymatic activity directly, the Ku-targeted approach is designed as a “precision off-switch.” This structural strategy is intended to reduce unwanted effects on normal tissues by focusing on the DNA-binding event required for pathway activation. The idea is to block the recognition of broken DNA ends rather than merely interrupt the catalytic machinery downstream.

During the first funding phase, the group discovered and optimized small molecules that can enter cells, interfere with DNA-PK activation, disrupt NHEJ-mediated repair, and sensitize cancer cells to radiation and radiomimetic agents in preclinical models. With the renewed NIH support, the researchers plan to define which DNA damage contexts and tumor vulnerabilities yield the strongest therapeutic windows for Ku-binding inhibitors.

A central goal in the next stage is identifying combination opportunities. The team will search for DNA double-strand break repair settings in which Ku-DBi compounds create synthetic lethal interactions—situations where cancer cells die when two pathways are effectively compromised, but normal cells tolerate the disruption better.

“Our next phase will investigate various DNA double-strand break repair contexts to identify novel therapeutic combinations with Ku-DBi’s,” Gavande said. Alongside these biological studies, the program will continue medicinal chemistry optimization to improve in vivo potency and delivery.

The ultimate target is a first-in-class Ku70/80 DNA-binding inhibitor platform that enhances radiotherapy effectiveness by undermining DNA repair dependence. If successful, the approach could offer a more selective route to radiosensitization across hard-to-treat solid tumors beyond lung cancer.

Subject of Research: Ku70/80 DNA-binding inhibitors to inhibit DNA-PK activation and radiosensitize lung cancer
Article Title: Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition
News Publication Date:
Web References: http://www.gavandelab.com/
References: National Cancer Institute/NIH award R01CA247370
Image Credits:

Keywords: cancer, DNA damage, DNA repair, DNA-PK, Ku70/80, NHEJ, radiotherapy, lung cancer, radiosensitization

Autoimmune diseases, characterized by the immune system’s misguided attack on the body’s own tissues, remain a formidable challenge in medicine. Th17 cells, a specialized subset of CD4+ T helper cells distinguished by their production of the cytokine IL-17, have long been implicated as central players driving inflammation in conditions such as multiple sclerosis, psoriasis, and rheumatoid arthritis. However, the detailed molecular circuitry controlling their pathogenicity has been elusive, impeding targeted clinical interventions.

The study, led by Chen and colleagues, reveals how sensing of DNA double-strand breaks—a form of severe DNA injury traditionally associated with cancer biology and genomic maintenance—also serves as a molecular switch in immune cells. The NHEJ system, a critical and conserved pathway tasked with repairing these DNA breaks, is now shown to extend its canonical roles into the realm of immune regulation. By stabilizing the transcriptional activity of RORγt, the NHEJ machinery effectively fine-tunes the gene expression programs underlying Th17 cell differentiation and their capacity to propagate autoimmune inflammation.

At the molecular level, Th17 cells often endure physiological stress that can induce transient DNA damage, including DSBs. These breaks, if unresolved, threaten cell viability, yet they also appear to serve as intracellular signals. The NHEJ system components recognize and mend these breaks, but along with repair, they interact with transcriptional regulators, preventing RORγt degradation. This stabilization ensures sustained expression of genes critical for the Th17 phenotype and their inflammatory functions. The study delineates this crosstalk with unprecedented clarity, supported by a suite of biochemical assays and genomic analyses.

Importantly, the effect of the NHEJ system on RORγt is not a mere background process but a decisive factor dictating the pathogenicity of Th17 cells. Enhanced transcriptional activity of RORγt correlates with increased production of inflammatory mediators, thereby exacerbating autoimmune pathology. Conversely, disruption of the NHEJ-dependent stabilization mechanism diminishes Th17 cell pathogenic potential, attenuating disease severity in experimental models. This causative link underscores the therapeutic significance of targeting the NHEJ-RORγt axis.

Beyond the mechanistic insights, the study pioneers new conceptual territory in immunology by positioning DNA damage sensing as a dynamic regulator of immune cell fate. Unlike the classical narrative where DNA repair solely preserves genomic integrity, this research reveals a dual role encompassing immune modulation. Such functional versatility of DNA repair pathways enriches our understanding of cellular physiology and suggests broader implications for other immune subsets and pathological contexts.

The researchers employed state-of-the-art methodologies, including CRISPR-based gene editing to selectively impair NHEJ components in Th17 cells, cutting-edge ChIP-seq to map RORγt binding landscapes, and single-cell RNA sequencing that resolved the heterogeneity of Th17 populations under DNA damage conditions. Together, these approaches built a compelling evidence base connecting DNA repair mechanisms directly to transcription factor dynamics and immune cell behavior.

Intriguingly, this newly characterized pathway appears selectively active in pathogenic Th17 cells but not their non-pathogenic counterparts or other T cell subtypes. This specificity offers a strategic window for therapeutic interventions aimed at dampening autoimmune inflammation without broadly suppressing the immune system, a common drawback of current immunosuppressive drugs. By honing in on the NHEJ-RORγt interaction, future drug development could achieve greater precision with fewer adverse effects.

The translational potential of these findings extends to biomarkers as well. Components of the NHEJ system or modified forms of RORγt stabilized by DNA damage sensing could serve as molecular signatures to identify highly pathogenic Th17 cells in patients. This would aid in disease prognosis and monitoring responses to treatments designed to disrupt this axis. Thus, the study’s ramifications go beyond bench science to inform clinical practice.

Beyond autoimmunity, this research opens new research avenues exploring whether similar DNA damage sensing mechanisms influence immune responses in infection, cancer immunotherapy, or chronic inflammation. The versatility of the NHEJ system hints at wider immunomodulatory roles yet to be uncovered, potentially involving memory T cells or regulatory T cells. The cross-disciplinary nature of this work seamlessly integrates fields of DNA repair, transcription regulation, and immunology.

Notably, the research also raises intriguing questions about the origin and regulation of DNA damage in immune cells. While traditionally viewed as detrimental, controlled DNA breaks might be an intrinsic component of immune cell activation and fate decisions. Further studies will be necessary to dissect how these endogenous breaks are generated and balanced to prevent deleterious mutations while enabling functional plasticity.

As autoimmune diseases continue to impact millions worldwide, the identification of molecular circuits wielding influence over disease-driving immune cells holds immense promise. This study’s unmasking of the interface between DNA double-strand break repair and RORγt stabilization represents a conceptual leap that challenges previous paradigms and encourages innovative therapeutic strategies. By revealing that immune cells use DNA damage sensing not only for survival but also to calibrate their inflammatory potential, researchers have added a new dimension to our understanding of immune regulation.

In conclusion, Chen and colleagues have provided an elegant model illustrating how DNA repair pathways intersect with immune transcriptional networks to govern disease-relevant functions. Their work shines a spotlight on the extraordinary adaptability of cellular machinery and underscores the value of diving deep into fundamental biological processes to uncover transformative insights. As the field moves forward, this study will likely serve as a touchstone inspiring novel approaches to diagnose, treat, and ultimately prevent autoimmune pathologies through molecular precision.

This remarkable confluence of genome maintenance and immune modulation sets the stage for a new era in immunotherapy, where manipulating DNA damage response elements may hold the key to taming harmful inflammation without compromising host defense. The elucidation of the NHEJ-dependent stabilization of RORγt marks a pivotal advance, signaling a future where tailored interventions harness the cell’s own repair mechanisms to recalibrate immune functions, offering hope to patients burdened by chronic autoimmune conditions.

Subject of Research:
Deciphering how DNA double-strand break sensing by the NHEJ repair system regulates transcriptional activity of RORγt and shapes the pathogenicity of Th17 cells in autoimmune diseases.

Article Title:
Sensing of DNA double-strand breaks by the NHEJ system stabilizes RORγt transcriptional activity and shapes Th17 pathogenicity in autoimmunity.

Article References:
Chen, GY., Zhu, WJ., Li, Z. et al. Sensing of DNA double-strand breaks by the NHEJ system stabilizes RORγt transcriptional activity and shapes Th17 pathogenicity in autoimmunity. Cell Res (2026). https://doi.org/10.1038/s41422-025-01204-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41422-025-01204-6

CHEK2, widely recognized as a key player in the DNA damage response (DDR) pathway, traditionally functions as a tumor suppressor by orchestrating precise repair mechanisms following double-stranded DNA breaks. Specifically, CHEK2 facilitates homologous recombination (HR), an error-free repair pathway crucial for maintaining genome stability. Loss of CHEK2 function disrupts this precise repair system, forcing cells to compensate by resorting to the more error-prone non-homologous end joining (NHEJ) pathway. This shift not only leads to the gradual accumulation of somatic mutations but also increases tumor mutational burden (TMB), a factor increasingly correlated with better immunotherapy outcomes due to the generation of neoantigens recognizable by immune cells.

The new review, spearheaded by researchers from Northwestern University Feinberg School of Medicine, highlights a dual mechanism whereby CHEK2 deficiency potentially amplifies anti-tumor immune responses. First, the elevated mutational burden arising from deficient HR repair generates an array of neoantigens, alerting cytotoxic T cells (especially CD8+ subsets) to the presence of malignant cells. Second, and perhaps more intriguingly, the review elucidates the role of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway as a secondary mechanism influenced by CHEK2 loss. DNA fragments generated by inaccurate repair escape the nucleus, accumulating in the cytosol where cGAS recognizes them as aberrant. This recognition activates the STING pathway, triggering a cascade that culminates in the production of Type I interferons and chemotactic cytokines, fostering a pro-inflammatory microenvironment conducive to robust T cell recruitment.

This intricate interplay between deficient DNA repair and innate immune activation elucidates why CHEK2-deficient tumors may demonstrate heightened infiltration of immune effectors. Notably, in cancers traditionally resistant to ICIs, such as glioblastoma and renal cell carcinoma, reduced CHEK2 expression correlated with increased CD8+ T cell presence and elevated expression of interferon-stimulated genes. These findings hint at the immunomodulatory potential of CHEK2 as not merely a bystander but an active participant in shaping the immune landscape of solid tumors, altering the paradigm by which tumor immunogenicity is understood.

Moreover, the research underscores the translational potential of these insights through examples of clinical investigations employing CHEK inhibitors alongside ICIs. Prexasertib, a dual CHEK1/2 inhibitor, has surfaced in early-stage trials demonstrating promising synergistic effects with PD-1 blockade. These preliminary data suggest that pharmacological inhibition of CHEK2 might potentiate immune activation within the tumor microenvironment, potentially sensitizing otherwise refractory cancers to immunotherapy.

The broader implications of this review extend to the identification of CHEK2 as a biomarker with prognostic and predictive utility. Determining CHEK2 status in patients could refine immunotherapy stratification, enabling clinicians to pinpoint those most likely to benefit from checkpoint blockade. This capability would represent a significant stride toward personalized cancer treatment, optimizing therapeutic outcomes while minimizing unnecessary exposure to ineffective modalities.

Fundamentally, this research enriches our understanding of the crosstalk between DNA repair pathways and immune regulation. The prevailing view perceives DDR genes as guardians of genome integrity alone; however, CHEK2 emerges as a bridge linking genomic instability to immune activation. By dictating the balance between error-free and error-prone repair, CHEK2 indirectly governs the generation of cytosolic DNA fragments that stimulate innate immune pathways, illustrating an elegant feedback mechanism that could be leveraged therapeutically.

The authors also address the complexities inherent in targeting CHEK2, not least the duality of its functions. While loss of CHEK2 augments immune visibility by increasing mutation-derived neoantigens and activating cGAS-STING signaling, complete inhibition might also exacerbate genomic instability with unpredictable consequences. Therefore, therapeutic strategies demand cautious design, possibly integrating precise dosing regimens or combinatory approaches that engage multiple aspects of tumor biology and immune regulation.

This review invites further inquiry into the molecular nuances of CHEK2’s immunomodulatory roles. Delineating the temporal dynamics of cGAS-STING activation in response to DNA damage and the interplay with other immune checkpoints could unravel additional layers of regulation. Moreover, exploring the heterogeneity across tumor types in CHEK2 expression and function might reveal subtype-specific vulnerabilities, tailoring interventions even further.

Beyond the laboratory, these findings resonate with ongoing clinical efforts to overcome cancer’s notorious evasiveness. By illuminating the nexus between defective DNA repair and immune activation, the study paves the way for innovative combination therapies that exploit intrinsic tumor weaknesses. As such, it reinforces the concept that successful immunotherapy requires not only immune targeting but also strategic modulation of tumor biology to unlock the immune system’s full potential.

In conclusion, the emerging paradigm positions CHEK2 as a pivotal molecular switch at the crossroads of DNA repair and immune surveillance. Harnessing this dual functionality holds the promise of enhancing immunotherapy efficacy and expanding treatment horizons for patients with solid tumors. As research advances, the integration of CHEK2 status evaluation and CHEK-targeted therapies may redefine cancer management, exemplifying the power of translational science to transform patient outcomes.

Subject of Research: Cells

Article Title: Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors

News Publication Date: 10-Jun-2025

Web References:

• https://www.oncotarget.com/archive/v16/
• http://dx.doi.org/10.18632/oncotarget.28740

Image Credits: Copyright © 2025 Qian et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords: cancer, CHEK2, immune checkpoint inhibitors, immunomodulation